Oral mucositis: Time for more studies

Yesid Alvarado, Lisa A. Bellm, Francis J. Giles*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Oral Mucositis (OM) is a frequent cause of severe morbidity in patients receiving chemotherapy and/or radiotherapy. The pathophysiology of OM involves direct cytotoxic effects, local inflammatory responses, and alterations in oral microflora. There are currently no approved agents for the prevention or treatment of OM. In this review we briefly describe current knowledge of the pathophysiology, clinical presentation, and management of OM. We then discuss investigational agents being studied in OM with a particular focus on local antimicrobial agents, hemopoietic growth factors, and cytokines. Measures to reduce the incidence of OM and/or alleviate its clinical sequelae should be incorporated into all chemotherapy or radiotherapy studies.

Original languageEnglish (US)
Pages (from-to)281-289
Number of pages9
Issue number5
StatePublished - Oct 2002


  • Antimicrobials
  • Hemopoietic growth factors
  • Keratinocyte growth factors
  • Oral mucositis
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Oral mucositis: Time for more studies'. Together they form a unique fingerprint.

Cite this